Ocular Therapeutix Participates in Upcoming Scientific Conferences

Ocular Therapeutix to participate in upcoming scientific conferences in July and August 2025, including OIS Retina 2025, ASRS 2025, and Women in Ophthalmology (WIO 2025). The company will present on various topics related to drug delivery and retinal disease, including its investigational product candidate AXPAXLI for wet age-related macular degeneration.

Ocular Therapeutix, a leading innovator in retinal disease treatment, has announced its participation in several upcoming scientific conferences in July and August 2025. The company will be presenting on various topics related to drug delivery and retinal disease, including its investigational product candidate AXPAXLI for wet age-related macular degeneration (AMD).

Ocular Therapeutix will be showcasing its research and innovations at the OIS Retina 2025 conference, the ASRS 2025 conference, and the Women in Ophthalmology (WIO 2025) conference. These conferences provide a platform for the company to engage with fellow researchers, clinicians, and industry professionals, sharing the latest advancements in retinal disease treatment and drug delivery technologies.

The company's investigational product candidate, AXPAXLI, is designed to address the unmet needs in wet AMD treatment. AXPAXLI is currently being evaluated in a phase 3 clinical trial, SOL-R, which aims to assess the safety and efficacy of the drug in patients with wet AMD. The trial, which recently completed enrollment, will evaluate AXPAXLI in at least 555 patients in a multi-center, double-masked, randomized (2:2:1), 3-arm study [3].

Ocular Therapeutix's participation in these conferences is part of its ongoing commitment to advancing the field of ophthalmology and improving patient outcomes. The company's focus on innovation and collaboration is reflected in its involvement in key scientific events and its dedication to developing novel treatment options for retinal diseases.

References:
[1] https://www.ophthalmologytimes.com/clinical/amd
[2] https://www.ophthalmologytimes.com/clinical/amd
[3] https://www.ophthalmologytimes.com/clinical/amd